High levels of circulating endothelial microparticles in patients with acute coronary syndromes

Leon Bernal-Mizrachi, Wenche Jy, Joaquin J Jimenez, Juan Pastor, Lucia M. Mauro, Lawrence L. Horstman, Eduardo De Marchena, Yeon Ahn

Research output: Contribution to journalArticle

309 Citations (Scopus)

Abstract

Background: Endothelial injury plays a critical role in coronary artery disease (CAD), but the assessment of this injury has been problematical. Recently, it has been shown in vitro that endothelial cells (ECs) release endothelial microparticles (EMPs) on activation or apoptosis and that an assay of EMPs can provide useful information on EC status in patients with thrombotic disorders. This study is aimed at assessing possible correlations between EMPs, which are markers of endothelial injury, and clinical subgroups of patients with CAD. Methods: A prospective, case-controlled study was conducted on 84 patients with CAD and 42 control subjects to investigate EMP profiles. Included were 64 patients with acute coronary syndromes ([ACS], 38 with myocardial infarction [MI] and 26 with unstable angina [UA]) and 20 patients with stable angina (SA). EMPs in platelet-poor plasma were measured flow cytometrically with combinations of fluorescent antibodies (anti-CD31, -51, -42), allowing distinction of EMPs from platelet microparticles (PMPs). Clinical subgroups of patients were correlated with EMP and PMP levels in blood. Results: Two species of EMPs (CD31 + and CD51 +) were evaluated. Both were significantly higher in patients with CAD than in control subjects. CD31 + EMP was higher in ACS than SA. Among patients with first MI, CD31 + EMP was higher in patients with MI than in patients with UA and was significantly higher than in patients with recurring MI. CD51 + EMP did not discriminate ACS from SA. A simultaneous assay of PMP showed correlation between EMPs and PMPs. However, PMPs did not discriminate patients with SA from control subjects. Conclusions: EMP assay appears promising for assessing EC injury in CAD.

Original languageEnglish
Pages (from-to)962-970
Number of pages9
JournalAmerican Heart Journal
Volume145
Issue number6
DOIs
StatePublished - Jun 1 2003

Fingerprint

Acute Coronary Syndrome
Blood Platelets
Stable Angina
Coronary Artery Disease
Myocardial Infarction
Endothelial Cells
Unstable Angina
Wounds and Injuries
Anti-Idiotypic Antibodies
Apoptosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

High levels of circulating endothelial microparticles in patients with acute coronary syndromes. / Bernal-Mizrachi, Leon; Jy, Wenche; Jimenez, Joaquin J; Pastor, Juan; Mauro, Lucia M.; Horstman, Lawrence L.; De Marchena, Eduardo; Ahn, Yeon.

In: American Heart Journal, Vol. 145, No. 6, 01.06.2003, p. 962-970.

Research output: Contribution to journalArticle

Bernal-Mizrachi, Leon ; Jy, Wenche ; Jimenez, Joaquin J ; Pastor, Juan ; Mauro, Lucia M. ; Horstman, Lawrence L. ; De Marchena, Eduardo ; Ahn, Yeon. / High levels of circulating endothelial microparticles in patients with acute coronary syndromes. In: American Heart Journal. 2003 ; Vol. 145, No. 6. pp. 962-970.
@article{ab8b39c4c0b64fbaba12da383de3dbc8,
title = "High levels of circulating endothelial microparticles in patients with acute coronary syndromes",
abstract = "Background: Endothelial injury plays a critical role in coronary artery disease (CAD), but the assessment of this injury has been problematical. Recently, it has been shown in vitro that endothelial cells (ECs) release endothelial microparticles (EMPs) on activation or apoptosis and that an assay of EMPs can provide useful information on EC status in patients with thrombotic disorders. This study is aimed at assessing possible correlations between EMPs, which are markers of endothelial injury, and clinical subgroups of patients with CAD. Methods: A prospective, case-controlled study was conducted on 84 patients with CAD and 42 control subjects to investigate EMP profiles. Included were 64 patients with acute coronary syndromes ([ACS], 38 with myocardial infarction [MI] and 26 with unstable angina [UA]) and 20 patients with stable angina (SA). EMPs in platelet-poor plasma were measured flow cytometrically with combinations of fluorescent antibodies (anti-CD31, -51, -42), allowing distinction of EMPs from platelet microparticles (PMPs). Clinical subgroups of patients were correlated with EMP and PMP levels in blood. Results: Two species of EMPs (CD31 + and CD51 +) were evaluated. Both were significantly higher in patients with CAD than in control subjects. CD31 + EMP was higher in ACS than SA. Among patients with first MI, CD31 + EMP was higher in patients with MI than in patients with UA and was significantly higher than in patients with recurring MI. CD51 + EMP did not discriminate ACS from SA. A simultaneous assay of PMP showed correlation between EMPs and PMPs. However, PMPs did not discriminate patients with SA from control subjects. Conclusions: EMP assay appears promising for assessing EC injury in CAD.",
author = "Leon Bernal-Mizrachi and Wenche Jy and Jimenez, {Joaquin J} and Juan Pastor and Mauro, {Lucia M.} and Horstman, {Lawrence L.} and {De Marchena}, Eduardo and Yeon Ahn",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0002-8703(03)00103-0",
language = "English",
volume = "145",
pages = "962--970",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - High levels of circulating endothelial microparticles in patients with acute coronary syndromes

AU - Bernal-Mizrachi, Leon

AU - Jy, Wenche

AU - Jimenez, Joaquin J

AU - Pastor, Juan

AU - Mauro, Lucia M.

AU - Horstman, Lawrence L.

AU - De Marchena, Eduardo

AU - Ahn, Yeon

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Background: Endothelial injury plays a critical role in coronary artery disease (CAD), but the assessment of this injury has been problematical. Recently, it has been shown in vitro that endothelial cells (ECs) release endothelial microparticles (EMPs) on activation or apoptosis and that an assay of EMPs can provide useful information on EC status in patients with thrombotic disorders. This study is aimed at assessing possible correlations between EMPs, which are markers of endothelial injury, and clinical subgroups of patients with CAD. Methods: A prospective, case-controlled study was conducted on 84 patients with CAD and 42 control subjects to investigate EMP profiles. Included were 64 patients with acute coronary syndromes ([ACS], 38 with myocardial infarction [MI] and 26 with unstable angina [UA]) and 20 patients with stable angina (SA). EMPs in platelet-poor plasma were measured flow cytometrically with combinations of fluorescent antibodies (anti-CD31, -51, -42), allowing distinction of EMPs from platelet microparticles (PMPs). Clinical subgroups of patients were correlated with EMP and PMP levels in blood. Results: Two species of EMPs (CD31 + and CD51 +) were evaluated. Both were significantly higher in patients with CAD than in control subjects. CD31 + EMP was higher in ACS than SA. Among patients with first MI, CD31 + EMP was higher in patients with MI than in patients with UA and was significantly higher than in patients with recurring MI. CD51 + EMP did not discriminate ACS from SA. A simultaneous assay of PMP showed correlation between EMPs and PMPs. However, PMPs did not discriminate patients with SA from control subjects. Conclusions: EMP assay appears promising for assessing EC injury in CAD.

AB - Background: Endothelial injury plays a critical role in coronary artery disease (CAD), but the assessment of this injury has been problematical. Recently, it has been shown in vitro that endothelial cells (ECs) release endothelial microparticles (EMPs) on activation or apoptosis and that an assay of EMPs can provide useful information on EC status in patients with thrombotic disorders. This study is aimed at assessing possible correlations between EMPs, which are markers of endothelial injury, and clinical subgroups of patients with CAD. Methods: A prospective, case-controlled study was conducted on 84 patients with CAD and 42 control subjects to investigate EMP profiles. Included were 64 patients with acute coronary syndromes ([ACS], 38 with myocardial infarction [MI] and 26 with unstable angina [UA]) and 20 patients with stable angina (SA). EMPs in platelet-poor plasma were measured flow cytometrically with combinations of fluorescent antibodies (anti-CD31, -51, -42), allowing distinction of EMPs from platelet microparticles (PMPs). Clinical subgroups of patients were correlated with EMP and PMP levels in blood. Results: Two species of EMPs (CD31 + and CD51 +) were evaluated. Both were significantly higher in patients with CAD than in control subjects. CD31 + EMP was higher in ACS than SA. Among patients with first MI, CD31 + EMP was higher in patients with MI than in patients with UA and was significantly higher than in patients with recurring MI. CD51 + EMP did not discriminate ACS from SA. A simultaneous assay of PMP showed correlation between EMPs and PMPs. However, PMPs did not discriminate patients with SA from control subjects. Conclusions: EMP assay appears promising for assessing EC injury in CAD.

UR - http://www.scopus.com/inward/record.url?scp=0038620493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038620493&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(03)00103-0

DO - 10.1016/S0002-8703(03)00103-0

M3 - Article

VL - 145

SP - 962

EP - 970

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 6

ER -